import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-cjc-1295-no-dac-research-guide",
  title: "Where to Buy CJC-1295 No DAC: A Researcher's Sourcing Guide",
  description:
    "What researchers need to know before sourcing CJC-1295 No DAC (Modified GRF 1-29) — how it differs chemically from DAC-modified versions, purity requirements, COA documentation standards, stability considerations, and sourcing red flags.",
  category: "Quality & Testing",
  readMinutes: 10,
  publishedAt: "2026-06-06",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "CJC-1295 No DAC — more precisely designated Modified GRF 1-29 (Mod GRF 1-29) — is a 29-amino acid growth hormone-releasing hormone (GHRH) analog derived from the active fragment of endogenous human GHRH. It differs from native GHRH (1-29) by four amino acid substitutions that enhance metabolic stability: Ala at position 2 is replaced by D-Ala (D2-substitution that resists DPP-IV cleavage), Gln at position 8 is replaced by Aib (prevents oxidation at Met), Ala at position 15 is replaced by Ala (maintains helical structure), and Leu at position 27 is replaced by Nle (prevents Met oxidation). These modifications produce a compound with a half-life of approximately 30 minutes — substantially longer than native GHRH (2–4 minutes) but without the albumin-binding Drug Affinity Complex (DAC) linker present in its longer-acting variant.",
    },
    {
      type: "paragraph",
      text: "The distinction matters for sourcing: CJC-1295 No DAC and CJC-1295 With DAC are different compounds with different pharmacokinetics, different dosing protocols, and different synthesis complexity profiles. This guide addresses the No DAC variant specifically.",
    },
    {
      type: "heading",
      text: "Chemical Complexity and What It Means for Synthesis Quality",
    },
    {
      type: "paragraph",
      text: "At 29 amino acids (MW 3367.9 Da), Modified GRF 1-29 is a demanding synthesis target. Its four non-standard substitutions require each corresponding building block — D-Ala, Aib (alpha-aminoisobutyric acid), and Nle (norleucine) — to be sourced, verified for chiral purity, and incorporated with high coupling efficiency. The Aib substitution at position 8 is particularly relevant to sourcing: Aib is a sterically hindered alpha,alpha-disubstituted amino acid with slow coupling kinetics in SPPS. Incomplete coupling at this position produces a truncated 21-residue sequence (the 1-7 + 9-29 mismatch fragment) that has substantially reduced GHRH receptor affinity and won't replicate the published biological activity of Mod GRF 1-29.",
    },
    {
      type: "paragraph",
      text: "Suppliers who use automated SPPS without extended coupling times at the Aib position systematically produce lower-quality batches that pass visual inspection but fail the receptor-binding activity of research-grade material. This is not detectable from appearance alone — only HPLC with mass spectrometry can confirm the Aib coupling was successful.",
    },
    {
      type: "heading",
      text: "Purity Standards for CJC-1295 No DAC Research",
    },
    {
      type: "paragraph",
      text: "≥98% HPLC purity (peak area at 220 nm) is the accepted research-grade threshold. At 29 residues, a 95% pure sample contains approximately 5% synthesis byproducts — which at typical research concentrations represents a non-trivial molar quantity of co-administered impurities. For GH axis studies where pulsatile GH release amplitude and timing are the endpoints, those impurities introduce dose-response noise that erodes experimental reproducibility.",
    },
    {
      type: "paragraph",
      text: "Mass spectrometry confirmation of the correct MW (3367.9 Da) is mandatory. The four non-standard substitutions that define Mod GRF 1-29 are not distinguishable from native GHRH (1-29) by HPLC retention time alone — they are structurally similar enough that a poorly characterized product could be misidentified. MS confirms identity, not just purity.",
    },
    {
      type: "heading",
      text: "What a Complete CJC-1295 No DAC COA Should Include",
    },
    {
      type: "list",
      items: [
        "HPLC chromatogram: retention time, peak area percentage, column and mobile phase details, UV wavelength (220 nm)",
        "Mass spectrometry confirmation of MW 3367.9 Da — multi-charge ions are common for a 29-residue peptide; the deconvoluted mass must match",
        "Appearance: white to off-white lyophilized powder",
        "Water content (Karl Fischer) for accurate peptide mass calculation",
        "Endotoxin testing (LAL, <1.0 EU/mg) for in vivo models",
        "Lot number, synthesis date, and expiration date",
        "Third-party laboratory header — not vendor-internal documentation",
      ],
    },
    {
      type: "heading",
      text: "No DAC vs. With DAC: Why Researchers Need to Verify What They're Buying",
    },
    {
      type: "paragraph",
      text: "CJC-1295 With DAC adds a maleimido-propionamide (MPA) reactive group that forms a covalent bond with lysine residues on circulating albumin, extending the half-life to approximately 8 days. CJC-1295 No DAC lacks this linker entirely and has a half-life of ~30 minutes. These are not interchangeable compounds: replicating a study designed around one requires using the correct variant, and the dosing protocols in the literature are specific to the pharmacokinetic profile of each form.",
    },
    {
      type: "paragraph",
      text: "The market creates confusion here because some vendors label Modified GRF 1-29 as 'CJC-1295 No DAC,' while others use the two names separately. Regardless of the label, researchers should confirm via COA that the product has MW ~3367.9 Da (No DAC) rather than ~3648.2 Da (With DAC), and that no reactive MPA group is present in the mass spectrum.",
    },
    {
      type: "heading",
      text: "Research Applications and Why Purity Matters",
    },
    {
      type: "paragraph",
      text: "CJC-1295 No DAC is used in GH axis research to study pulsatile GH secretion, the somatotroph response to GHRH analogs, and the combined effects of GHRH analogs with GHRPs (such as Ipamorelin) that potentiate GH pulse amplitude through synergistic receptor activation. This combined GHRH/GHRP research model requires both components to be verified quality — impure Mod GRF 1-29 introduces a variable that can obscure the synergistic signal the study is designed to detect.",
    },
    {
      type: "paragraph",
      text: "Aging research using GH secretagogues as a model for age-related GH axis decline is another application context. Older rodent models have attenuated GH pulses by design; detecting Mod GRF 1-29's effect in a blunted-response system requires the full dose of active compound, not a fraction of it diluted by synthesis impurities.",
    },
    {
      type: "heading",
      text: "Stability and Storage",
    },
    {
      type: "paragraph",
      text: "Lyophilized CJC-1295 No DAC is stable at -20°C for 24+ months in sealed vials. The norleucine substitutions protect against the Met oxidation that would degrade native GHRH, which is one of the key stability advantages of the Mod GRF 1-29 sequence. Once reconstituted in sterile or bacteriostatic water, solutions should be stored at 4°C and used within 4 weeks. Protect from light and avoid repeated freeze-thaw of reconstituted solutions.",
    },
    {
      type: "heading",
      text: "Red Flags in the CJC-1295 No DAC Market",
    },
    {
      type: "list",
      items: [
        "No mass spectrometry data — without MS, researchers cannot confirm they received No DAC vs. With DAC, or that the four non-standard substitutions were correctly incorporated",
        "Purity below 98% — at 29 residues with Aib coupling complexity, sub-98% signals a synthesis quality problem",
        "Vendor conflates CJC-1295 No DAC and Modified GRF 1-29 without clarifying they are the same compound — indicates product knowledge gaps",
        "No endotoxin data — important for any in vivo application given CJC-1295 No DAC's primary research use in animal models",
        "Shipping without cold-pack — lyophilized peptides degrade at sustained ambient temperature, particularly at the Aib residue which affects structural integrity",
        "No third-party lab attribution on COA — vendor-internal testing has no independent verification",
      ],
    },
    {
      type: "heading",
      text: "Why Nexphoria",
    },
    {
      type: "paragraph",
      text: "Nexphoria's CJC-1295 No DAC is synthesized using extended coupling protocols at Aib-containing positions, with independent HPLC and MS verification on every lot. We use the Modified GRF 1-29 designation in our documentation to avoid the naming ambiguity in the market, and our COAs confirm MW of 3367.9 Da — not the DAC variant. Purity is ≥99% HPLC by third-party testing.",
    },
    {
      type: "paragraph",
      text: "GH axis research depends on pharmacokinetically precise compounds. The difference between No DAC and With DAC isn't a minor variant — it changes the experimental design entirely. We make sure researchers get exactly what the protocol requires.",
    },
    {
      type: "disclaimer",
      text: "CJC-1295 No DAC (Modified GRF 1-29) is sold by Nexphoria strictly for in vitro and preclinical research use. It is not approved for human consumption, therapeutic use, or veterinary application. All purchases require agreement to our research-use-only terms.",
    },
  ],
};
